Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer

Pancreatic Carcinoma Clinical Trial

Official title:

Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04082455
• Other study ID #: SPHIC-TR-PaCa2018-03
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 1, 2018
• Est. completion date: June 1, 2024

Study information

• Verified date: November 2023
• Source: Shanghai Proton and Heavy Ion Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for locally advanced pancreatic carcinoma (LAPC)

Description:

The carbon dose of 60-67.5GyE in 15 fractions was delivered to clinical target volume (CTV). The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 49
• Est. completion date: June 1, 2024
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. The histologically or cytologically confirmed, or the clinically diagnosed by clinical diagnosis criterion proposed by Pancreatic Cancer Committee of Chinese Anti-Cancer Association, which was based on evidences of (1). Typical symptoms of abdominal and/or back pain; (2). CA19-9 increased over the normal up limit; (3). A pancreatic mass shown on CT or MRI; and (4). SUV of PET-CT in mass increased compared to that in normal pancreas;

2. Unresectable LAPC defined by the criteria of (NCCN) guidelines (Version 1. 2013), or refusal to surgery;

3. Gastrointestinal tract (GI) not invaded;

4. ECOG Performance Status 0-1 within 30 days prior to registration;

5. Age of = 18 years old;

6. Enough hematological function (white blood cell count = 3.0×109/L; platelets =50×109/L; hemoglobin = 90 g/L);

7. Enough liver and kidney functions (creatinine <110gmol/L; urea nitrogen <7.1mmol/L; bilirubin < 1.5 x ULN, ALT and AST = 2.5 x ULN);

8. No evidence of distant metastases, based upon PET, CT, or MRI images of the chest, abdomen and pelvis within 30 days prior to registration;

9. Informed consent form obtained.

Exclusion Criteria:

1. No pathological evidence of malignant tumor;

2. ECOG>=2;

3. Liver, kidney and bone marrow function are poor and not adequate for treatment;

4. Side effect of previous treatment is not covered yet, eg. The interval between TACE and other anti-tumor therapy is less than one month;

5. Prior radiation therapy to the abdomen or radioactive particle implantation;

6. cardiac pacemaker or other metal implantation whose function may be disturbed by high energy beam or which affect the dose in target volume;

7. Dose constrain of normal liver, digested system and other OAR could not reach the expecting safe dose constrain;

8. The patient could not get benefit from proton or heavy ion radiotherapy in physician's opinion;

9. Comitant diseases or affecters which could affect the proton or heavy ion radiotherapy;

10. Pregnancy(blood or urine ß-HCG certified)or lactation;

11. Drug or alcohol abused;

12. HIV positive, including received anti-retrovirus treatment; chronic hepatitis B virus replication stage; hepatitis C active stage; syphilis active stage;

13. HBV positive, hepatitis B virus replication stage, need to be treated with anti-virus treatment, but could not receive anti-virus treatment because of comitant disease;

14. Psychiatric history, possibly affecting the completion of treatment;

15. patients with serious complications that might affect radiotherapy, including 1)unstable angina pectoris requiring hospitalization in the last 6 months,congestive heart failure,myocardial infarction; 2)acute bacterial or systemic fungal infections; 3)exacerbation of chronic obstructive pulmonary disease ( COPD) or other respiratory system disease requiring hospitalization 4)hepatic function insufficiency or renal function insufficiency 5) immunosuppressed patients

16. patients with connective tissue disease such as active scleroderma or lupus and so on, which is contraindication for radiotherapy

17. patients can't understand treatment goal or unwilling/unable to sign up inform consent form;

18. no civil capability or limited civil capacity.

Related Conditions & MeSH terms

• Pancreatic Carcinoma
• Pancreatic Neoplasms

Intervention

Radiation:
• carbon ion radiotherapy
carbon ion radiotherapy

Locations

Country	Name	City	State
China	Shanghai Proton and Heavy Ion Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Proton and Heavy Ion Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Time interval from the start of radiotherapy to 3 months after the completion of radiotherapy
Secondary	overall survival rate	overall survival rate	2 years
Secondary	local progression-free survival	local progression-free survival	2 years
Secondary	progression-free survivals	progression-free survivals	2 years